Platelet Responsiveness and Outcome from Platelet Transfusion (PROmPT)

Not Applicable

Completed

• Conditions: ational Cancer Research Network, Blood; Cancer

• Registration Number: ISRCTN56366401
• Lead Sponsor: HS Blood and Transplant [NHSBT] (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-19
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

1. Age 16 years or older
2. Stable Haematology/Oncology Patients at Addenbrooke?s Hospital
3. Thrombocytopenia secondary to bone marrow failure, requiring platelet transfusions according to local and British Committee for Standards in Haematology (BCSH) Guidelines
4. Patients who, if peripheral venous access for blood sampling is required, have adequate access and will consent to their blood being taken in this way
5. Patients able to give written informed consent
6. Male or female

Exclusion Criteria

1. Inherited or acquired clotting disorders
2. Inherited or acquired platelet function disorders
3. Current Acute Promyelocytic Leukaemia
4. Previously documented WHO Grade 4 bleeding (debilitating blood loss)
5. Palpable Splenomegaly
6. Immunological refractoriness to platelet transfusion
7. Require HLA or HPA matched platelets
8. Pregnant or lactating women
9. Other active malignancy in past 5 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Count increment at 1 hour; measured as difference between pre and 1 hour post transfusion count. Corrected for dose and BSA.

Secondary Outcome Measures

Name	Time	Method
1. 24 hour count increment measured as difference between pre and 24 hour count<br>2. Bleeding Score - both patient and clinician assessed<br>3. Red cell transfusion measured as number of red cell units transfused<br>4. Time to next platelet transfusion measured as number of days to next transfusion